65,437 trials
Post-operative Pain · Quadriceps Muscle Strength
Primary: Quadriceps Muscle Strength in Kilogram-force (Kgf) — 1.1; 0.0 Kilogram-force (Kgf) — p=0.026
Refractory Mixed Type Melasma
Primary: Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up — -5.6; 4.7 score on a scale
Wound Infection
Primary: Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond — 41; 54 Participants
Hypoxia
Primary: End-tidal Oxygen — 78.1; 78.6 End tidal oxygen saturation percentage
Movement Disorders · Depth of Anesthesia Monitors
Primary: Correlation Between Bispectral (BIS) and Response Entropy (RE) Indices — 96; 96; 65; 77 units on a scale
Irritable Bowel Syndrome
Primary: Irritable Bowel Syndrome Quality of Life — 34.25; 58.19 score on a scale
Chronic Hepatitis B
Primary: Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest — 75.0; 87.5; 37.5; 75.0 Percentage of Participants
Carcinoma, Non-Small-Cell Lung
Primary: Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib — 27.6; 27.7 Months
Breastfeeding
Primary: Number of Participants Completing Qualitative Interviews on the Peer Counselling Breastfeeding Intervention — 5; 0; 1; 0 Participants
COPD
Primary: FEV1 AUC0-4 — 0.292; 0.288; 0.177; 0.189 Liters
Leukemia
Primary: Participants With a Response — 49; 19 Participants
Arterial Stiffening · Aging · Menopause
Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1
Group B Strep Infection
Primary: Number of Participants With Treatment Emergent Adverse Events — 17; 15; 8 Participants
Coordination, Administrative
Primary: Health Care System Hassles Scale — 5.20; 4.71; 4.78; 4.30 units on a scale
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Prioritized Healthcare Topics — 90; 79; 23; 22 participants — p=.91